Tenax Therapeutics, Inc. (TENX)

Tenax Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	105.46	94.85	9.79	2.12	5.58	6.25
Short-Term Investments	-	-	-	-	-	0.46
Cash & Short-Term Investments	105.46	94.85	9.79	2.12	5.58	6.71
Cash Growth	1023.85%	868.66%	361.09%	-61.97%	-16.82%	24.32%
Other Current Assets	0.4	1.84	1.89	1.08	0.11	0.08
Total Current Assets	105.86	96.69	11.68	3.21	5.69	6.8
Net Property, Plant & Equipment	-	-	-	0.19	0.29	0.06
Other Long-Term Assets	-	-	0	0.01	0.01	0.01
Total Assets	105.86	96.69	11.69	3.4	5.99	6.87
Accounts Payable	0.56	3.16	2.07	0.45	0.86	0.76
Accrued Expenses	1.97	1.54	1.01	0.78	0.7	1.24
Short-Term Debt	-	-	0.5	0.62	-	0.12
Total Current Liabilities	2.53	4.69	3.59	1.85	1.56	2.12
Long-Term Debt	-	-	-	-	-	0.12
Long-Term Leases	-	-	-	0.06	0.18	-
Total Long-Term Liabilities	-	-	-	0.06	0.18	0.12
Total Liabilities	2.53	4.69	3.59	1.91	1.75	2.24
Common Stock	-	-	-	0	0	0
Additional Paid-in Capital	439.44	406.85	305.35	291.03	282.74	250.64
Accumulated Other Comprehensive Income	-	-	-	-	-	-0
Retained Earnings	-336.11	-314.86	-297.25	-289.54	-278.49	-246.02
Shareholders' Equity	103.33	91.99	8.1	1.49	4.24	4.63
Total Liabilities & Equity	105.86	96.69	11.69	3.4	5.99	6.87
Total Debt	0	0	0.5	0.69	0.18	0.24
Net Cash (Debt)	105.46	94.85	9.29	1.44	5.4	6.47
Net Cash Growth	11.19%	920.89%	547.37%	-73.42%	-16.51%	21.14%
Net Cash Per Share	3.16	6.21	37.40	78.04	419.91	998.40
Book Value	103.33	91.99	8.1	1.49	4.24	4.63
Book Value Per Share	3.09	6.02	32.59	81.17	330.05	713.97
Tangible Book Value	103.33	91.99	8.1	1.49	4.24	4.63
Tangible Book Value Per Share	3.09	6.02	32.59	81.17	330.05	713.97

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q